Vast Therapeutics

This week Founder and Chief Scientific Officer Mark Schoenfisch is at RDD 2024 and is presenting some exciting results from Vast Therapeutics' orally inhaled ALX1 development program for the treatment of chronic respiratory infections. Poster Title: Efficacy of Inhaled ALX1 in a Model of Chronic Pseudomonas Aeruginosa Infection Session: 2 - From Bench to Bedside (P8) Location: Arizona Ballroom “Treating respiratory infections safely and effectively remains a significant hurdle,” stated Dr. Mark Schoenfisch, Chief Scientific Officer at Vast Therapeutics. “Our study suggests that a nitric oxide-releasing prodrug delivered in a nebulized format is achievable and superior to standard of care (Tobramycin), which is exciting because nitric oxide does not engender resistance and should result in a more favorable tolerability profile than conventional antibiotics.” To view the poster click here: https://lnkd.in/eCajn9GK

This week Founder and Chief Scientific Officer Mark Schoenfisch is at RDD 2024 and is presenting some exciting results from Vast Therapeutics' orally inhaled ALX1 development program for the treatment of chronic respiratory infections. Poster Title: Efficacy of Inhaled ALX1 in a Model of Chronic Pseudomonas Aeruginosa Infection Session: 2 - From Bench to Bedside (P8) Location: Arizona Ballroom “Treating respiratory infections safely and effectively remains a significant hurdle,” stated Dr. Mark Schoenfisch, Chief Scientific Officer at Vast Therapeutics. “Our study suggests that a nitric oxide-releasing prodrug delivered in a nebulized format is achievable and superior to standard of care (Tobramycin), which is exciting because nitric oxide does not engender resistance and should result in a more favorable tolerability profile than conventional antibiotics.” To view the poster click here: https://lnkd.in/eCajn9GK

Vast Therapeutics announces an upcoming presentation at the 2024 Respiratory Innovation Summit being held in San Diego May 17-18, 2024. Dr. Nathan Stasko, Chief Executive Officer of Vast, will deliver an oral presentation on how its lead candidate, ALX1, is positioned to reshape the treatment landscape for several patient populations chronically infected with Pseudomonas aeruginosa. 2024 RIS Showcase Presentation Details: Session Title: Showcase Two: COVID, Infectious Disease and Other Innovators Session Date and Time: Saturday, May 18 at 10:15 a.m. PT Location: Manchester Grand Hyatt San Diego More information on the ATS 2024 Respiratory Innovation Summit can be found at https://lnkd.in/dJEGTQ3U.

Exciting news today published by Vast Founder and Chief Scientific Officer, Mark Schoenfisch. "The broad-spectrum activity of our drug candidate plus the ability to kill mycobacteria that have invaded immune cells without engendering antimicrobial resistance is unprecedented." As a company we look forward to accelerating this technology into the clinic in 2024, as NTM pulmonary disease is a growing public health concern without alternatives to maintenance antibiotics that continue to propagate global antibiotic resistance. #antibioticresistance #ntm #copd #cysticfibrosis